Apatinib, a tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptor-2 (VEGFR-2), may synergize with TACE in treating HCC patients via inhibiting angiogenesis in the tumor hypoxic environment caused by TACE [10–13]. The gene discussed is KDR; the disease is hepatocellular carcinoma.